Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,920,383

« Back to Dashboard

Which drugs does patent 8,920,383 protect, and when does it expire?


Patent 8,920,383 protects RYZODEG 70/30, TRESIBA, SAXENDA, LEVEMIR FLEXTOUCH, NORDITROPIN FLEXPRO, XULTOPHY 100/3.6, and NOVOLOG FLEXTOUCH, and is included in seven NDAs.

This patent has eight patent family members in nine countries.

Summary for Patent: 8,920,383

Title:Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Abstract: A mechanism for preventing setting of a dose, which exceeds the amount of a medicament in a reservoir in an injection device. The device comprises a threaded piston rod, a limiter and a driver. The three elements are arranged such that during dose setting, the limiter is moved towards an end-of-contend position, wherein dose setting is limited. The invention comprises an accumulative and a non-accumulative embodiment. The invention further relates to a mechanism for prevention ejection of a dose exceeding the set dose.
Inventor(s): Enggaard; Christian Peter (Hillerod, DK), Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsvaerd, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:11/996,409
Patent Claim Types:
see list of patent claims
Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
RYZODEG 70/30
insulin aspart; insulin degludec
SOLUTION;SUBCUTANEOUS203313-001Sep 25, 2015RXYesYes8,920,383► SubscribeY
Novo Nordisk Inc
TRESIBA
insulin degludec
SOLUTION;SUBCUTANEOUS203314-001Sep 25, 2015RXYesNo8,920,383► SubscribeY
Novo Nordisk Inc
TRESIBA
insulin degludec
SOLUTION;SUBCUTANEOUS203314-002Sep 25, 2015RXYesYes8,920,383► SubscribeY
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes8,920,383► SubscribeY
Novo Nordisk Inc
LEVEMIR FLEXTOUCH
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-005Oct 31, 2013RXYesYes8,920,383► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,920,383

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05016291Jul 27, 2005
PCT Information
PCT FiledJuly 17, 2006PCT Application Number:PCT/EP2006/007004
PCT Publication Date:February 15, 2007PCT Publication Number: WO2007/017052

International Patent Family for Patent: 8,920,383

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany602006020453► Subscribe
Denmark1909870► Subscribe
European Patent Office1909870► Subscribe
Spain2361563► Subscribe
Japan2009502273► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot